This site is intended for healthcare professionals outside the US.


Consistent results across all prespecified subgroups1

“AFINITOR (everolimus) plus exemestane showed a positive treatment effect across all prespecified subgroups compared with exemestane plus placebo”
The prespecified exploratory subgroup analyses were observational in nature; as such, there were no prespecified statistical procedures controlling for type 1 errors.
*AFINITOR is indicated for the treatment of hormone receptor–positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a nonsteroidal aromatase inhibitor.
 Other than NSAI.
aBC, advanced breast cancer; AFI, AFINITOR; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; ECOG, Eastern Cooperative Oncology Group; EXE, exemestane; HR+, hormone receptor-positive; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival; PgR, progesterone receptor; PBO, placebo.
Adapted with kind permission from Springer Science+Business Media: Adv Ther. Everolimus Plus Exemestane in Postmenopausal Patients With HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. 2013;30(10):870-884. Yardley DA, Noguchi S, Pritchard KI, et al. Figure 2.
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884.